Published 2021-07-15
Ahmad Kholis Soetojo Wahjoe Djatisoesanto


Objective: To evaluate the effectiveness of TNF-α inhibitor therapy in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) patients compared to placebo, assessed using Global Response Assessment (GRA). Material & Methods: A systematic review and meta-analysis. Subjects were patients with moderate to severe diagnosis of BPS/IC who were given TNF-α inhibitor versus placebo, with the Global Response Assessment (GRA) (patient-reported self-reported BPS/IC treatment response scale). A systematic literature search was carried out on the English databases PubMed/MEDLINE and Science  Direct, published until September 2020. Data were extracted independently and assessed the bias and quality of each selected article. Results: Initially there were 124 studies. After further selection, 2 RCT studies were included in the criteria for this study. The number of samples obtained was 85 patients. There is 1 study that used 400 mg of certolizumab pegol subcutaneously and 1 study used adalimumab 80 mg subcutaneously and followed by 40 mg subcutaneously for 2 weeks. Both studies had statistically low heterogeneity with I2 = 0% (P = 0.34), so fixed effect statistical model was used to determine the result. Furthermore, there was no significant difference (P = 0.32) between the number of GRA responders from the TNF-α inhibitor and placebo therapy groups, with odds ratio of 1.61 (CI = 0.65-4.00). Conclusion: TNF-α inhibitor therapy did not increase GRA responders when compared to placebo.



bladder pain syndrome, global response assessment, interstitial cystitis, TNF alpha inhibitor


Davis NF, Gnanappiragasam S, Thornhill JA. Interstitial cystitis/painful bladder syndrome: The influence of modern diagnostic criteria on epidemiology and on Internet search activity by the public. Transl Androl Urol. 2015; 4(5): 506–11.

Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the united states. J Urol. 2011; 186(2): 540–4.

Suskind AM, Berry SH, Suttorp MJ, Elliott MN, Hays RD, Ewing BA, et al. Health-related quality of life in patients with interstitial cystitis/bladder pain syndrome and frequently associated comorbidities. Qual Life Res. 2013; 22(7): 1537–41.

Vasudevan V, Moldwin R. Addressing quality of life in the patient with interstitial cystitis/bladder pain syndrome. Asian J Urol. 2017; 4(1): 50–4.

Propert KJ, Payne C, Kusek JW, Nyberg LM. Pitfalls in the design of clinical trials for interstitial cystitis. Urology. 2002; 60(5): 742–8.

Dellis AE, Kostakopoulos N, Papatsoris AG. Is there an effective therapy of interstitial cystitis/bladder pain syndrome? Expert Opin Pharmacother. 2019; 20(12): 1417–9.

Keay S. Cell signaling in interstitial cystitis/painful bladder syndrome. Cell Signal. 2008; 20(12): 2174–9.

Kawamorita N, Yoshikawa S, Kashyap M, Tyagi P, Arai Y, Chancellor MB, et al. Liposome Based Intravesical Therapy Targeting Nerve Growth Factor Ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis. J Urol. 2016; 195(6): 1920–6.

Rao Q, Chen Y, Yeh CR, Ding J, Li L, Chang C, et al. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. Oncotarget. 2016; 7(7): 7842–55.

Mykoniatis I, Katafigiotis I, Sfoungaristos S, Yutkin V. Immunotherapy options for painful bladder syndrome: what’s the potential? Expert Opin Biol Ther. 2017; 17(12): 1471–80.

Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014; 191(1): 77–82.

Bosch PC. A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. Eur Urol. 2018; 74(5): 623–30.

Wang H, Russell LJ, Kelly KM, Wang S, Thipphawong J. Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. BMC Urol. 2017; 17(1): 1–8.

Sampson J. Selection. Vis Commun Q. 2006; 13(2): 110–5.

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343(7829): 1–9.

Offiah I, McMahon SB, O’Reilly BA. Interstitial cystitis/bladder pain syndrome: Diagnosis and management. Int Urogynecol J. 2013; 24(8): 1243–56.

Syed LJ, Ilchak DL. Bladder Pain Syndrome in Females. J Nurse Pract. 2017; 13(4): 291–5.

Hanno P, Lin A, Nordling J, Nyberg L, Van Ophoven A, Ueda T, et al. Bladder pain syndrome international consultation on incontinence. Neurourol Urodyn. 2010; 29(1): 191–8.

Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014; 191: 77–82.

Chuang YC, Chermansky C, Kashyap M, Tyagi P. Investigational drugs for bladder pain syndrome (BPS)/interstitial cystitis (IC). Expert Opin Investig Drugs. 2016; 25(5): 521–9.

Logadottir Y, Delbro D, Fall M, Gjertsson I, Jirholt P, Lindholm C, et al. Cytokine Expression in Patients with Bladder Pain Syndrome/Interstitial Cystitis ESSIC Type 3C. J Urol. 2014; 192(5): 1564–8.

Zhang E, Zhu X, Han S, Peng Z, Wang W, Li J, et al. Increased expression of TNF ligand-related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis. Exp Ther Med. 2013; 5(1): 282–6.

Evans RJ, Moldwin RM, Cossons N, Darekar A, Mills IW, Scholfield D. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011; 185(5): 1716–21.

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University